Latest News

An international survey shows vitiligo drives stigma, sun avoidance, and daily limits, urging better treatment guidance and mental health support.

Lisa Pruett, MD, FAAD, shares evidence-based acne care, debunks summer retinoid myths, and explains how Glo2Facial oxygenation and exfoliation support clearer skin and fade marks.

As payers escalate automated denial programs targeting dermatology's E/M claims, the data shows practices that appeal consistently win, yet fewer than 1% ever do.

New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.

Verrica Pharmaceuticals and Japanese partner Torii Pharmaceutical have each dosed a first patient in COVE-3, the second pivotal phase 3 trial testing Ycanth for common warts.

Neal Bhatia, MD, led an Evolving Paradigms event on advancing multidisciplinary care in cutaneous squamous cell carcinoma to compare systemic immunotherapy data and referral practices.

AbbVie’s $10.9B deal adds Apogee’s long-acting IL-13 and TSLP antibodies to its portfolio, aiming for less frequent dosing in atopic dermatitis and asthma.

Career decisions in dermatology are too often driven by emotion rather than data, according to a new practice management column examining common pitfalls in contract evaluation and compensation negotiations.

Derm-Biome Pharmaceuticals reported positive preclinical results for DB-006, a small molecule reducing itch, inflammation, and IgE levels in a model of atopic dermatitis.

As RAD kicks off in Nashville, Tennessee, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.

A new qualitative study finds that patients with hard-to-heal wounds routinely engage in protective and monitoring behaviors at home without recognizing those efforts as meaningful contributions to their own care.

The 3-phase Isoclear regimen pairs topical isotretinoin with clindamycin, tranexamic acid, niacinamide, and copper peptide based on treatment stage.

Before Revolutionizing Atopic Dermatitis 2026 begins, take a look back at the data, debates, and patient stories that defined last year’s Nashville meeting.